Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
Completed
Cyclacel Pharmaceuticals, Inc.
Phase 1
The goal of this study to find the highest tolerable dose of sapacitabine that can be given
to patients with advanced leukemias or myelodysplastic syndromes.
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
Terminated
Cyclacel Pharmaceuticals, Inc.
Phase 2
This is an open label, randomized phase II study designed to evaluate the tolerability and
response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell
lymphoma (CTCL) who have had progressive, recurrent, or persistent disease on or following 2
systemic therapies.
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
Completed
Cyclacel Pharmaceuticals, Inc.
Phase 2
The main objective of this study is to learn which sapacitabine treatment is more likely to
keep the cancer in check for at least one year in AML patients who are at least 70 years of
age or older and in MDS patients who are at least 60 years of age.
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Terminated
Cyclacel Pharmaceuticals, Inc.
Phase 2
This is an open label, single arm, phase II study to evaluate the safety and efficacy of oral
sapacitabine administered twice daily for 5 consecutive days every week for 2 weeks followed
by 7-day rest in patients who have had one prior chemotherapy regimen for advanced Non-Small
Cell Lung Cancer (NSCLC).
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
Unknown status
Cyclacel Pharmaceuticals, Inc.
Phase 1
The primary objective of this study is to determine the maximum tolerated dose (MTD) or
recommended phase II doses of sapacitabine and seliciclib administered sequentially or
concomitantly. The secondary objectives are to evaluate antitumor activity of this sequential
or concomitant treatment and to explore the pharmacodynamic effect of this treatment in skin
and peripheral blood mononuclear cells.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
